IMRX

Immuneering Corporation is a biotechnology company operating within the healthcare sector. It has a market capitalization of $426.81 million and employs 54 individuals. The company's scale is modest compared to larger industry peers. The financial health of Immuneering Corporation indicates significant losses, with net income and EBITDA both reported at negative values: -$62,496,372 and -$63,817,392, respectively. Free cash flow also falls into the red, totaling -$27,747,748. Cash reserves are substantial, standing at $227.56 million, but debt is minimal, at $3.92 million. The company's profitability metrics, including gross margin, operating margin, and profit margin, all register 0.0%. Returns on equity and assets are also negative: -43.8% and -25.9%, respectively. The valuation of Immuneering Corporation presents a mixed picture, with a forward P/E ratio of -4.14 and an EV/EBITDA ratio of -3.19. The price to book ratio is 1.84. The company's beta is reported at 0.47, indicating relatively low volatility compared to the broader market.